Relief from Menopausal Symptoms: Main Uses and Benefits

Klimadynon is commonly used in situations involving certain distressing symptoms of the menopausal transition, primarily targeting symptom clusters related to physical discomfort and heightened physiological activity.

Medicinal products containing this active ingredient are used for the relief of menopausal symptoms. It is relevant in clinical settings that involve acute or disruptive symptom patterns, helping to manage symptoms such as hot flashes, excessive sweating, nervousness, and occasional mood changes.

This type of symptomatic management is relevant when symptoms become more noticeable and create noticeable functional strain.

The medication provides support that helps ease the overall symptom burden, which assists with maintaining functional stability. This is also relevant for managing symptoms that interfere with daily comfort, supporting patients during difficult episodes by easing distress and helping them cope more steadily with symptom fluctuations during this phase.

---

Quick Fact: Symptomatic Support for Hot Flashes Klimadynon is commonly used to help with vasomotor symptoms, such as hot flashes and night sweats, which can become intense or disruptive.

Official Eligibility and Restriction Profile

The eligibility profile for Klimadynon is defined strictly by regulatory labeling, which establishes the approved population and lists specific exclusions and warnings based on clinical status.

Category	Official Regulatory Status
Populations for whom use is allowed	Adult menopausal patients are the only group for whom use is established.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance or to plants of the Ranunculaceae family (e.g., buttercup).
Age-related eligibility rules	Children and adolescents are excluded, as there is no use established in this therapeutic indication for these groups.
Pregnancy and lactation eligibility	Not recommended for use. Women of childbearing potential should consider using effective contraception during treatment.
Hormone-related restrictions	Should not be used together with oestrogens unless advised by a doctor.
Liver health restrictions	Not advised in cases of pre-existing liver damage. Patients must stop taking immediately if signs of liver injury develop.

Official regulatory documents classify the use of Klimadynon as contraindicated for women who have or have had oestrogen-sensitive tumours. Furthermore, the label requires mandatory medical consultation for patients with a history of liver disorder and advises that the preparation should not be taken without specific medical guidance.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Klimadynon (extract of Cimicifuga racemosa rhizomes) as specified in authoritative government regulatory documents.

---

Interaction Classifications and Restrictions

Classification	Interacting Entity	Regulatory Statement
Mandatory Restriction	Oestrogens (Estrogens)	Co-administration is formally restricted in regulatory labeling and should not occur without professional healthcare guidance.
Pharmacodynamic Caution	Potentially Hepatotoxic Agents	Co-administration with substances known to be hepatotoxic may theoretically increase the documented risk of liver-related adverse events.
Drug–Substance Interaction	Alcohol (Ethanol)	Included as a substance that contributes to the caution regarding potentially hepatotoxic agents.

---

Official Interaction Statements

Regulatory sources define the product's interaction profile by emphasizing two main constraints. The co-administration of Klimadynon with Oestrogens is subject to a formal restriction. Additionally, a pharmacodynamic caution exists regarding the concurrent use of substances classified as potentially hepatotoxic agents due to the possibility of an additive risk of liver injury. This caution also applies to the consumption of Alcohol. Regulatory documents officially state that there are no specific, clinically relevant pharmacokinetic interactions involving common metabolic enzymes or drug transporters that require mandatory restrictions for co-administration. Furthermore, official labeling does not specify any timing or separation requirements for administration relative to other medicinal products.

Central Neurotransmitter Modulation and Receptor Targeting

The active components act as partial agonists on key receptors in the brain, including specific serotonin receptors (5- HT7 and 5- HT1 A) and the mu-opioid receptor. This interaction engages mechanisms that modulate overactive or dysregulated processes in the central nervous system, establishing the molecular basis for the mechanism's influence on physiological signaling.

---

Hypothalamic Thermoregulatory Stabilization

The drug’s central action converges in the hypothalamus, the control center for thermal homeostasis. By modulating the local neurotransmitter balance, the mechanism helps to re-calibrate the thermoregulatory set-point, initiating or suppressing signaling sequences that result in a moderated physiological output from the thermoregulatory center.

---

Non-Hormonal Pathway Specificity

The medicine is defined by its non-estrogenic pathway specificity, meaning its effect is achieved without classical agonism at reproductive estrogen receptors. This ensures targeted pathway adjustment to central signaling, leading to a modulation of central pathways without involving the broad systemic effects typical of humoral hormone mechanisms.

Official Administration Guidelines

Klimadynon is a medicine for which the administration protocol is defined by standardized posology. The usage guidelines apply to female adults in the menopause and are focused on the oral route for two available dosage forms: film-coated tablets and an oral liquid solution.

---

Labeled Dosing and Administration

Parameter	Official Instruction
Route of Administration	Oral use is the sole approved method.
Standard Daily Dose	5.6 mg of the standardized dry extract.
Tablet Regimen	1 tablet containing 2.8 mg of the extract is taken twice daily.
Dosing Frequency	The dose is typically divided and administered in the morning and in the evening.
Administration Method	The film-coated tablets must be swallowed whole with liquid and must not be sucked.
Duration of Use	Continuous use of the medicine is formally restricted to a maximum period of six months without further medical advice.

---

Procedural Structure

The official instruction protocol establishes a precise use pattern. The standardized dose is taken via the oral route, often divided into two fixed daily time points, such as morning and evening. This procedural structure ensures that the total labeled daily intake of 5.6 mg of the dry extract is achieved, which corresponds to the 40 mg crude herbal substance equivalent used in historical posology. The final instruction restricts the total length of continuous administration to six months, defining the time-bound use context of the medicine.

The Research Base: Studies on Climacteric Complaints

The research for Klimadynon, which uses a specific ethanolic extract of black cohosh (Cimicifuga racemosa), includes studies examining symptom patterns and patient experiences during the menopausal transition. Researchers have used formal Randomized Controlled Trials (RCTs) and Systematic Reviews to study this specific preparation for the climacteric syndrome. Findings are highly specific to this particular ethanolic preparation (BNO 1055) and cannot be generalized to other black cohosh products.

Key Focus Areas: Vasomotor and Neurovegetative Symptoms

Studies have explored how the medicine was observed in women experiencing symptoms where episodes of heightened symptom activity become more noticeable. Research describes measurements recorded on functional scales for both vasomotor symptoms (like hot flushes and night sweats) and neurovegetative symptoms (like nervousness and sleep disturbances). Data show patterns related to how measured symptoms evolved during the trials, though some evaluations note that findings were sometimes mixed across all available research.

---

Duration of Evidence: Long-Term Studies and Follow-up

Most primary clinical research exploring short-term symptom changes was conducted over limited periods, typically spanning three months (12 weeks). While some open-label research has extended up to a year, long-term effects are not fully established based on the current body of high-quality, controlled evidence. Follow-up durations were limited, making it difficult to draw conclusions about the durability of the response.

---

Research in Defined Patient Groups

The specific extract was evaluated in adult women experiencing symptoms that vary in intensity. Research has explored patients categorized as having moderate-to-severe climacteric complaints. The evidence derived from these settings contributes to the broader evidence landscape. However, data for certain groups, such as those with pre-existing medical conditions (comorbidities), remain insufficient from the core clinical trial base.

---

Assessing the Strength and Limitations of the Evidence

Scientific bodies often describe the available data as providing exploratory evidence or evidence of moderate quality for the intended use. One key research limitation is that the primary analysis in a major controlled trial did not describe a clear distinction in the overall patient population, with further subgroup findings being explored in greater detail. Certainty remains low regarding the long-term profile of use, and research is continuing on long-term outcomes.

Common questions about Klimadynon (FAQ)

---

Q: What is Klimadynon used for?

According to official product information, Klimadynon is indicated for the relief of menopausal complaints. These typically include symptoms such as hot flushes and excessive sweating which are commonly experienced during menopause.

---

Q: How long does it take for Klimadynon to work?

Regulatory documents state that initial effects of the medicine are usually observed after approximately two weeks of continuous use. Further improvement may be observed with continued use.

---

Q: Can I take Klimadynon if I have liver problems?

The official product information advises that this medicine is not recommended if a person has existing liver damage. If signs of potential liver injury appear while using it, such as unusual fatigue or dark urine, the product information advises seeking medical advice immediately and stopping the medicine.

---

Q: Is Klimadynon a hormone replacement therapy (HRT)?

Klimadynon is not a hormone replacement therapy (HRT). It is officially classified as a traditional herbal medicinal product. Its active ingredient is an extract from the black cohosh rhizome (Cimicifuga racemosa), making it a non-hormonal treatment.

---

Q: What happens if I miss a dose of Klimadynon?

If a dose is forgotten, the product information advises that a person should not take a double dose to compensate. Instead, the official instructions advise continuing treatment by taking the next scheduled dose at the usual time.

---

Q: Can men take Klimadynon?

The product information clearly states that Klimadynon is not indicated for use in men. The medicine is intended solely for the treatment of specific menopausal complaints experienced by women.

---

Q: Is Klimadynon safe for people with breast cancer history?

Studies and official information indicate that individuals with a history of estrogen-dependent tumors, such as certain types of breast cancer, should only use this medicine after consulting a doctor. This is due to the theoretical risk associated with the medicine's effect profile.

---

Q: Is Klimadynon suitable for pregnant or breastfeeding women?

According to the official Summary of Product Characteristics, Klimadynon is contraindicated during both pregnancy and breastfeeding, meaning its use is restricted in these groups.

How to Store and Dispose of Klimadynon

Official regulatory documents define specific requirements for the storage and disposal of Klimadynon to ensure product stability and environmental safety.

---

Storage Requirements

Klimadynon must be stored at a temperature below 30, C. To maintain its integrity and for protection from light, the medicine must be kept in the original blister pack and outer carton.

For child safety, the product must be kept out of the sight and reach of children.

Product Stability and Disposal

Do not use the medicine after the expiry date shown on the carton. The medicine must not be disposed of via household waste or wastewater. Patients should ask their pharmacist for instructions on how to dispose of unused or expired products, as this practice is intended to help protect the environment.